Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 33

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 33
---
 the development and
expansion of our business. As a result, investors in the Ordinary Shares and Depositary Shares will benefit in the foreseeable future
only if the Ordinary Shares and Depositary Shares appreciate in value.

Any determination to pay dividends
in the future would be at the discretion of our Board of Directors and will depend upon our results of operations, cash requirements,
financial condition, contractual restrictions, and any future debt agreements and is subject to compliance with applicable laws, including
the Companies Act 2006 (as amended from time to time) of the United Kingdom, or the Companies Act, which requires English companies to
have profits available for distribution equal to or greater than the amount of the proposed dividend.

| 22 |

<div align='center'>CAPITALIZATION</div>

The following table sets forth
our capitalization as of June 30, 2025:

| · | on an actual basis; |

| · | on                                                                                                
 a pro forma basis to give effect to the sale and issuance, subsequent to June 30, 2025 through    
 the date of this registration statement, of 6,226,400,000 Ordinary Shares pursuant to the         
 terms of that certain a securities purchase agreement dated January 17, 2025, or ELOC, with       
 newly formed C/M Capital Master Fund LP, or the Investor, including 46,400,000 Ordinary Shares    
 to the Investor in satisfaction of a commitment fee, resulting in $0.4 million in gross proceeds; 
 and                                                                                               |

| · | on                                                                                         
 a pro forma as-adjusted basis to give further effect to the sale by us of 3,536,345 Units  
 in this offering at an assumed combined public offering price of $5.09 per Unit, assuming  
 (i) no sale of any Pre-Funded Units and (ii) no exercise of the Series L Warrants and the  
 Placement Agent Warrants, after deducting the estimated placement agent fees and estimated 
 offering expenses.                                                                         |

The
amounts shown below are unaudited and the pro forma and pro forma as-adjusted numbers represent management’s estimate. The pro
forma and pro forma as-adjusted information set forth in the table below is illustrative only and will be adjusted based on the actual
public offering price and other terms of this offering determined at pricing. The information in this table should be read in conjunction
with and is qualified by reference to the financial statements and notes thereto and other financial information contained in this prospectus